MX2020004836A - Agentes anticancerígenos. - Google Patents

Agentes anticancerígenos.

Info

Publication number
MX2020004836A
MX2020004836A MX2020004836A MX2020004836A MX2020004836A MX 2020004836 A MX2020004836 A MX 2020004836A MX 2020004836 A MX2020004836 A MX 2020004836A MX 2020004836 A MX2020004836 A MX 2020004836A MX 2020004836 A MX2020004836 A MX 2020004836A
Authority
MX
Mexico
Prior art keywords
treatment
barr virus
chemokine receptor
epstein barr
receptor modulators
Prior art date
Application number
MX2020004836A
Other languages
English (en)
Inventor
Gene Cutler
William Yew - Wai Ho
Paul David Kassner
Silpa Suthram
Brian Russell Wong
Original Assignee
Rapt Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rapt Therapeutics Inc filed Critical Rapt Therapeutics Inc
Publication of MX2020004836A publication Critical patent/MX2020004836A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

En el presente documento se desvelan métodos terapéuticos para administrar compuestos que modulan el receptor de quimiocina C-C de tipo 4 (CCR4) para el tratamiento de cánceres y neoplasias malignas positivos para el virus de Epstein Barr (VEB).
MX2020004836A 2017-11-06 2018-11-05 Agentes anticancerígenos. MX2020004836A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762582284P 2017-11-06 2017-11-06
US201862723415P 2018-08-27 2018-08-27
PCT/US2018/059284 WO2019090272A1 (en) 2017-11-06 2018-11-05 Chemokine receptor modulators for treatment of epstein barr virus positive cancer

Publications (1)

Publication Number Publication Date
MX2020004836A true MX2020004836A (es) 2020-10-16

Family

ID=64572480

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020004836A MX2020004836A (es) 2017-11-06 2018-11-05 Agentes anticancerígenos.

Country Status (15)

Country Link
US (1) US11730736B2 (es)
EP (1) EP3706750A1 (es)
JP (1) JP2021502345A (es)
KR (1) KR20200104291A (es)
CN (1) CN111918652A (es)
AU (1) AU2018360766B2 (es)
BR (1) BR112020009055A2 (es)
CA (1) CA3081750A1 (es)
IL (1) IL274444B2 (es)
MX (1) MX2020004836A (es)
RU (1) RU2020118594A (es)
SG (1) SG11202004105TA (es)
TW (1) TWI838350B (es)
WO (1) WO2019090272A1 (es)
ZA (1) ZA202002898B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2020118594A (ru) 2017-11-06 2021-12-09 Рапт Терапьютикс, Инк. Противораковые агенты
AU2019212478C1 (en) * 2018-01-26 2023-11-16 Rapt Therapeutics, Inc. Chemokine receptor modulators and uses thereof
MX2022005795A (es) * 2019-11-13 2022-06-08 Rapt Therapeutics Inc Formas cristalinas del antagonista del receptor de quimiocinas cc tipo 4 y usos de las mismas.
CN119585256A (zh) * 2022-04-06 2025-03-07 拉普特医疗公司 趋化因子受体调节剂及其用途
CN119301112A (zh) * 2022-06-02 2025-01-10 西藏海思科制药有限公司 一种杂环化合物ccr4抑制剂及其用途
TW202430519A (zh) * 2022-11-28 2024-08-01 大陸商上海美悅生物科技發展有限公司 螺雜環取代的嘧啶類化合物及其製備方法和用途
TWI870125B (zh) * 2022-11-28 2025-01-11 大陸商上海美悅生物科技發展有限公司 雜環取代的嘧啶類化合物及其製備方法和用途
TWI879384B (zh) * 2023-01-16 2025-04-01 大陸商上海美悅生物科技發展有限公司 雜環取代的吡嗪類化合物及其製備方法和用途
KR20240001559U (ko) 2023-03-14 2024-09-23 주식회사 베스타텍 프로파일을 이용한 조립식 대차 및 그를 포함하는 조립식 대차 세트
WO2024222736A1 (zh) * 2023-04-24 2024-10-31 浙江华海药业股份有限公司 趋化因子受体调节剂制备方法和用途
CN121039119A (zh) * 2023-05-02 2025-11-28 奥瑞基尼肿瘤有限公司 作为ccr4调节剂的稠合双环杂环基化合物
WO2025056065A1 (zh) * 2023-09-15 2025-03-20 上海医药集团股份有限公司 一种趋化因子受体拮抗剂、药物组合物和应用
CN120004907A (zh) * 2023-11-14 2025-05-16 上海美悦生物科技发展有限公司 螺杂环化合物、其制备方法、中间体和用途
WO2025237303A1 (zh) * 2024-05-14 2025-11-20 先声药业有限公司 β-葡萄糖脑苷脂酶变构调节剂、其药物组合物及用途
WO2026012376A1 (zh) * 2024-07-10 2026-01-15 浙江华海药业股份有限公司 趋化因子受体调节剂制备方法和用途

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5300498A (en) 1993-06-04 1994-04-05 Hoechst-Roussel Pharmaceuticals Incorporated 6-piperazinyl-1H-pyrazolo[3,4-b]pyridine-3-carboxylic acids, esters, amides and related compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
AP2001002304A0 (en) 1996-05-03 2001-12-31 Pfizer Substituted indazole derivatives and related compounds
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
US6488930B1 (en) 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
AU5960300A (en) 1999-07-15 2001-02-05 Nps Allelix Corp. Heterocyclic compounds for the treatment of migraine
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
BR0112224A (pt) 2000-07-07 2003-06-10 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto
HUP0301742A3 (en) 2000-07-07 2005-08-29 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
US20020173524A1 (en) 2000-10-11 2002-11-21 Tularik Inc. Modulation of CCR4 function
WO2002030357A2 (en) 2000-10-11 2002-04-18 Chemocentryx, Inc. Compounds and methods for modulating ccr4 function
TW593278B (en) 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
WO2002094264A1 (en) 2001-05-23 2002-11-28 Tularik Inc. Ccr4 antagonists
WO2003051876A1 (en) 2001-12-14 2003-06-26 Japan Tobacco Inc. Pyrazolopyridine derivatives and medicinal use thereof
AU2003252478A1 (en) 2002-07-10 2004-02-02 Ono Pharmaceutical Co., Ltd. Ccr4 antagonist and medicinal use thereof
EP1585548B1 (en) 2002-12-09 2018-06-27 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
SE0301650D0 (sv) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
SE0301654D0 (sv) * 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
US20050287138A1 (en) 2003-10-08 2005-12-29 Kyowa Hakko Kogyo Co., Ltd. CCR4-specific antibody composition
DE602004029934D1 (de) 2003-12-04 2010-12-16 Kyowa Hakko Kirin Co Ltd Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament
WO2006089290A1 (en) 2005-02-18 2006-08-24 Abraxis Bioscience Inc.. Combinations and modes of administration of therapeutic agents and combination therapy
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
WO2006101456A1 (en) 2005-03-21 2006-09-28 S*Bio Pte Ltd Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors
BRPI0615265A8 (pt) 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
US8034765B2 (en) 2005-08-31 2011-10-11 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
GB0525144D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525143D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
TW200730512A (en) 2005-12-12 2007-08-16 Astrazeneca Ab Novel compounds
US7807704B2 (en) 2006-03-30 2010-10-05 Chemocentryx, Inc. Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
WO2008045529A1 (en) 2006-10-12 2008-04-17 Serenex, Inc. Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases
PT2117520T (pt) 2006-12-14 2018-12-04 Abraxis Bioscience Llc Terapia do cancro da mama com base no estado do receptor do hormona com nanoparticulas compreendendo taxane
JP2010516812A (ja) 2007-01-30 2010-05-20 バイオジェン・アイデック・エムエイ・インコーポレイテッド 有糸分裂キナーゼの調節剤
AU2008340319A1 (en) * 2007-12-21 2009-07-02 Wyeth Llc Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use thereof
CA2721153C (en) 2008-04-10 2018-10-02 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
KR20150136137A (ko) 2008-04-10 2015-12-04 아브락시스 바이오사이언스, 엘엘씨 소수성 탁산 유도체의 조성물 및 그의 용도
PT2401270E (pt) 2009-02-26 2014-01-20 Glaxo Group Ltd Derivados de pirazole utilizados como antagonistas do receptor ccr4
WO2010118367A2 (en) 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
ES2502541T3 (es) 2009-09-10 2014-10-03 Kyowa Hakko Kirin Co., Ltd. Medicamento que incluye una composición de anticuerpos unida específicamente al receptor 4 de quimiocina CC humana (CCR4)
ES2648340T3 (es) * 2011-12-01 2018-01-02 Chemocentryx, Inc. Benzoimidazoles y benzopirazoles substituidos como antagonistas de CCR(4)
WO2013166500A1 (en) 2012-05-04 2013-11-07 Dana-Farber Cancer Institute, Inc. Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
MX2016015181A (es) 2014-05-21 2017-05-25 Pfizer Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
AU2015328273B2 (en) 2014-10-06 2020-09-17 Dana-Farber Cancer Institute, Inc. Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof
PL3490565T3 (pl) * 2016-07-29 2022-09-26 Rapt Therapeutics, Inc. Pochodne azetydyny jako modulatory receptora chemokinowego i ich zastosowanie
WO2018049271A1 (en) * 2016-09-09 2018-03-15 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
WO2018187509A1 (en) * 2017-04-04 2018-10-11 Flx Bio, Inc. Heterocyclic compounds as chemokine receptor modulators
RU2020118594A (ru) 2017-11-06 2021-12-09 Рапт Терапьютикс, Инк. Противораковые агенты

Also Published As

Publication number Publication date
KR20200104291A (ko) 2020-09-03
WO2019090272A1 (en) 2019-05-09
AU2018360766B2 (en) 2024-09-19
US20190134031A1 (en) 2019-05-09
BR112020009055A2 (pt) 2020-11-03
CA3081750A1 (en) 2019-05-09
TW201922251A (zh) 2019-06-16
RU2020118594A3 (es) 2021-12-29
ZA202002898B (en) 2022-12-21
TWI838350B (zh) 2024-04-11
IL274444A (en) 2020-06-30
EP3706750A1 (en) 2020-09-16
IL274444B1 (en) 2024-02-01
SG11202004105TA (en) 2020-06-29
JP2021502345A (ja) 2021-01-28
IL274444B2 (en) 2024-06-01
RU2020118594A (ru) 2021-12-09
US11730736B2 (en) 2023-08-22
AU2018360766A1 (en) 2020-05-21
CN111918652A (zh) 2020-11-10

Similar Documents

Publication Publication Date Title
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
MX394676B (es) Métodos para tratar el cáncer.
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
BR112018013733A2 (pt) combinações anti-cd20 para o tratamento de tumores a
CO2018008761A2 (es) Derivados de maitansinoide, conjugados de los mismos métodos de uso
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
BR112018077492A2 (pt) métodos de tratamento de câncer de ovário
MX390517B (es) Uso de moduladores del receptor de glucocorticoides para potenciar inhibidores de puntos de regulacion.
CL2018000293A1 (es) Compuestos heterocíclicos útiles como moduladores de factor de necrosis tumoral (tnf) alfa
CL2017002494A1 (es) Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer
MX2022005780A (es) Moduladores de receptores estrogenicos.
MX2018010709A (es) Terapia del cancer con un virus oncolitico combinado con un inhibidor de punto de control.
PH12015502161A1 (en) Therapeutic compounds and compositions
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
WO2019099977A3 (en) Indole compounds as aryl hydrocarbon receptor (ahr) modulators
PH12015502028A1 (en) Ido inhibitors
EP4691562A3 (en) Anti-pd-l1 combinations for treating tumors
MX366875B (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
CO2017004932A2 (es) Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva
ECSP18014798A (es) Inhibidores de ezh2
MX382824B (es) Uso de dianhidrogalactitol y analogos y derivados de los mismos para tratar glioma maligno recurrente o tumor cerebral secundario progresivo.
BR112018008882A2 (pt) método para tratar um distúrbio proliferativo e produto farmacêutico
EP4599893A3 (en) Cg0070 for treating bcg resistant bladder carcinoma in situ
JOP20200244A1 (ar) مشتقات بلاديينوليد كعوامل تستهدف جسيمات الوصل لعلاج السرطان
CL2019000662A1 (es) Inhibidores de dopamina–b–hidroxilasa.